Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Committee Charters

Listed below are individual charters for each of our committees which outline the conditions by which each committee operates.

Audit Committee Charter
Compensation Committee Charter
Corporate Governance and Nominating Committee Charter